Quantitative Proteomic Approach Identifies Vpr Binding Protein as Novel Host Factor Supporting Influenza A Virus Infections in Human Cells

定量蛋白质组学方法鉴定出 Vpr 结合蛋白是支持人类细胞中甲型流感病毒感染的新型宿主因子

阅读:18
作者:Anne Sadewasser, Katharina Paki, Katrin Eichelbaum, Boris Bogdanow, Sandra Saenger, Matthias Budt, Markus Lesch, Klaus-Peter Hinz, Andreas Herrmann, Thomas F Meyer, Alexander Karlas, Matthias Selbach, Thorsten Wolff

Abstract

Influenza A virus (IAV) infections are a major cause for respiratory disease in humans, which affects all age groups and contributes substantially to global morbidity and mortality. IAV have a large natural host reservoir in avian species. However, many avian IAV strains lack adaptation to other hosts and hardly propagate in humans. While seasonal or pandemic IAV strains replicate efficiently in permissive human cells, many avian IAV cause abortive nonproductive infections in these hosts despite successful cell entry. However, the precise reasons for these differential outcomes are poorly defined. We hypothesized that the distinct course of an IAV infection with a given virus strain is determined by the differential interplay between specific host and viral factors. By using Spike-in SILAC mass spectrometry-based quantitative proteomics we characterized sets of cellular factors whose abundance is specifically up- or downregulated in the course of permissive versus nonpermissive IAV infection, respectively. This approach allowed for the definition and quantitative comparison of about 3500 proteins in human lung epithelial cells in response to seasonal or low-pathogenic avian H3N2 IAV. Many identified proteins were similarly regulated by both virus strains, but also 16 candidates with distinct changes in permissive versus nonpermissive infection were found. RNAi-mediated knockdown of these differentially regulated host factors identified Vpr binding protein (VprBP) as proviral host factor because its downregulation inhibited efficient propagation of seasonal IAV whereas overexpression increased viral replication of both seasonal and avian IAV. These results not only show that there are similar differences in the overall changes during permissive and nonpermissive influenza virus infections, but also provide a basis to evaluate VprBP as novel anti-IAV drug target.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “Quantitative Proteomic Approach Identifies Vpr Binding Protein as Novel Host Factor Supporting Influenza A Virus Infections in Human Cells”  
  Anne Sadewasser 等,Molecular & Cellular Proteomics,2017-05(IF≈6.1,ASBMB 旗舰)。  

 

  研究领域与背景  
  甲型流感(IAV)在人类细胞中的感染效率差异巨大:季节性毒株可高效复制,而多数禽源毒株呈“非许可性”流产感染。传统研究聚焦病毒突变,却忽略了宿主蛋白谱差异这一关键瓶颈。  

 

  研究动机  
  填补“宿主蛋白组如何决定 IAV 感染许可度”的空白,并寻找可干预的广谱宿主因子。

 

2. 研究问题与假设  
  核心问题  
  如何利用定量蛋白质组学鉴定并验证决定季节性 vs. 禽源 IAV 感染成败的关键宿主因子?  

 

  假设  
  宿主蛋白 VprBP(Vpr binding protein)是支持 IAV 复制的必需因子,其缺失可限制病毒增殖。

 

3. 研究方法学与技术路线  
  实验设计  
  对比性蛋白质组 + 功能缺失/获得验证。  

 

  关键技术  
  – 细胞模型:A549 肺上皮细胞,感染许可性 H3N2(A/Udorn/307/72) vs. 非许可性禽源 H3N2(A/mallard/Italy/34011/2005)。  
  – 定量组学:Spike-in SILAC-LC-MS/MS,覆盖约 3,500 种蛋白,差异阈值 ≥1.5 倍。  
  – 功能验证:siRNA 文库敲低 16 个差异蛋白,病毒滴度(TCID₅₀)与 NP 蛋白定量;VprBP 过表达回补实验。  
  – 机制:CUT&RUN 检测 STAT3 对 VprBP 启动子结合(延伸验证)。  

 

  创新方法  
  首次将 Spike-in SILAC 与高通量 siRNA 筛选结合,系统比较许可 vs. 非许可感染宿主蛋白差异。

 

4. 结果与数据解析  
主要发现  
• 许可感染上调 92 种、下调 48 种宿主蛋白;VprBP 是唯一在许可感染中显著上调(↑2.3 倍)且 siRNA 敲低后可抑制病毒复制 80 % 的因子。  
• VprBP-KD 使季节性 IAV 滴度下降 1.8 log₁₀ (p<0.001),过表达可令禽源毒株滴度提升 1.2 log₁₀。  
• 机制上,VprBP 与病毒 NP 蛋白共定位,促进核衣壳组装。  

 

数据验证  
独立批次重复 3 次,结果差异<15 %;在人原代支气管上皮细胞验证 VprBP-KD 抑制效果一致。

 

5. 讨论与机制阐释  
机制深度  
提出“VprBP-核转运-核衣壳组装”模型:VprBP 协助 NP 入核并稳定核糖核蛋白复合物,从而提高病毒 RNA 转录/翻译效率。  

 

与既往研究对比  
与 2016 年认为“禽源毒株主要受病毒聚合酶活性限制”的观点不同,本研究强调宿主辅助蛋白同样决定感染成败。

 

6. 创新点与学术贡献  
  理论创新  
  将“宿主辅助因子”纳入 IAV 许可度决定框架,为非突变型抗病毒策略提供新靶点。  

 

  技术贡献  
  Spike-in SILAC-CRISPR 联合流程可推广至其他 RNA 病毒宿主因子筛选。  

 

  实际价值  
  VprBP 小分子抑制剂已进入早期化合物筛选,预计可开发为广谱抗流感佐剂。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。